

Clinical Utility of Exercise Training in Heart Failure with Reduced and Preserved Ejection Fraction

Muhammad Asrar Ul Haq¹⁻³, Cheng Yee Goh¹, Itamar Levinger⁴, Chiew Wong^{1,3} and David L. Hare^{2,3}

¹Northern Heart, The Northern Hospital, Melbourne, Vic, Australia. ²Austin Health, Melbourne, Vic, Australia. ³University of Melbourne, Melbourne, Vic, Australia. ⁴Institute of Sport, Exercise and Active Living (ISEAL), College of Sport and Exercise Science, Victoria University, Melbourne, Australia.

ABSTRACT: Reduced exercise tolerance is an independent predictor of hospital readmission and mortality in patients with heart failure (HF). Exercise training for HF patients is well established as an adjunct therapy, and there is sufficient evidence to support the favorable role of exercise training programs for HF patients over and above the optimal medical therapy. Some of the documented benefits include improved functional capacity, quality of life (QoL), fatigue, and dyspnea. Major trials to assess exercise training in HF have, however, focused on heart failure with reduced ejection fraction (HFREF). At least half of the patients presenting with HF have heart failure with preserved ejection fraction (HFPEF) and experience similar symptoms of exercise intolerance, dyspnea, and early fatigue, and similar mortality risk and rehospitalization rates. The role of exercise training in the management of HFPEF remains less clear. This article provides a brief overview of pathophysiology of reduced exercise tolerance in HFREF and heart failure with preserved ejection fraction (HFPEF), and summarizes the evidence and mechanisms by which exercise training can improve symptoms and HF. Clinical and practical aspects of exercise training prescription are also discussed.

KEYWORDS: heart failure, exercise, HFPEF

CITATION: Asrar ul Haq et al. Clinical Utility of Exercise Training in Heart Failure with Reduced and Preserved Ejection Fraction. *Clinical Medicine Insights: Cardiology* 2015;9 1-9 doi: 10.4137/CMC.S21372.

RECEIVED: November 05, 2014. **RESUBMITTED:** December 29, 2014. **ACCEPTED FOR PUBLICATION:** January 04, 2015.

ACADEMIC EDITOR: Thomas E. Vanhecke, Editor in Chief

TYPE: Review

FUNDING: Itamar Levinger is supported by a Future Leader Fellowship (ID 100040) from the National Heart Foundation of Australia. The authors confirm that this funder had no influence over the study design, content of the article, or selection of this journal.

COMPETING INTERESTS: Authors disclose no potential conflicts of interest.

COPYRIGHT: © the authors, publisher and licensee Libertas Academica Limited. This is an open-access article distributed under the terms of the Creative Commons CC-BY-NC 3.0 License.

CORRESPONDENCE: muhammad.asrar@unimelb.edu.au

Paper subject to independent expert blind peer review by minimum of two reviewers. All editorial decisions made by independent academic editor. Upon submission manuscript was subject to anti-plagiarism scanning. Prior to publication all authors have given signed confirmation of agreement to article publication and compliance with all applicable ethical and legal requirements, including the accuracy of author and contributor information, disclosure of competing interests and funding sources, compliance with ethical requirements relating to human and animal study participants, and compliance with any copyright requirements of third parties. This journal is a member of the Committee on Publication Ethics (COPE).

Introduction

Heart failure (HF) is a chronic and debilitating illness that is becoming an increasingly important burden on the health care system. The American Heart Association (AHA) reported the prevalence of HF in American population as 2.6% in 2006, with more than 200,000 deaths associated with HF.¹ There is good evidence that the burden of HF syndrome is increasing in the developed countries mainly because of improved survival and aging population. Approximately 550,000 individuals in the United States are diagnosed with HF annually, and this number is anticipated to increase to 1.5 million by 2040. Recent large epidemiological studies have established that at least one-half of patients with HF indeed have preserved

ejection fraction (EF), termed as heart failure with preserved ejection fraction (HFPEF), and that this portion of the HF population predominantly consists of women, older age group, and people with hypertension and other cardiovascular risk factors.² The prevalence of HFPEF within the population varies from 1.14% to 5.5%, depending on the age of the population.² To establish a diagnosis of HF, the contemporary guidelines warrant the presence of symptoms and signs specific to HF, and objective evidence of cardiac dysfunction, usually by echocardiography. Similarly, three obligatory conditions need to be satisfied to diagnose HFPEF are clinical signs and symptoms of HF, normal or near normal systolic function, and diastolic dysfunction.^{3,4}



Exercise training for HF patients is well established as an adjunct therapy. Until only three decades ago, bed rest and the restriction of exercise were recommended for people with HF. This concept, however, was challenged in 1980s. The first study on the effects of exercise in HF was published in 1990,⁵ which reported improvement of HF symptoms and physical capacity with exercise training, without adverse events. The authors concluded that the belief that bed rest was beneficial in preserving the hearts of HF patients could no longer be accepted. This was followed by further studies that suggest that reduced exercise tolerance is in fact an independent predictor of hospital readmission and mortality in patients with HF.^{6,7} Today, an exercise program is formally recommended as an important and safe treatment for HF patients.^{8–10}

The aims of this review are (1) to discuss the clinical and practical aspects of exercise training prescription, (2) provide a brief account of pathophysiology of reduced exercise tolerance in HF, and (3) summarize the evidence and mechanisms by which exercise training can improve symptoms of HF in people with heart failure with reduced ejection fraction (HFREF) and heart failure with preserved ejection fraction (HFPEF). Databases including Ovid EMBASE, Ovid MEDLINE, and PubMed were searched for terms (heart failure, diastolic heart failure, heart failure with normal ejection fraction, heart failure with preserved ejection fraction, exercise training, cardiac rehabilitation) up to December 2014.

Exercise Prescription in HF Patients

Most contemporary guidelines generally suggest an aerobic activity of at least 30 minutes for five or more days per week. There is a great variation between the exercise programs and the level of intensity in HF trials. Clinically, an intensity range of 70–80% of peak heart rate (HR) is usually deemed as sufficient when a symptom-limited exercise protocol is utilized. The rating of perceived exertion (RPE) has also been used as an indicator for work intensity and as a tool in the prescription of exercise training intensity.¹¹ The RPE score has been shown to be reliable and valid, and it has a moderate to high correlation (r range, 0.57–0.89) with respiratory variables, HR, and blood lactate in healthy men.¹² In HF, patients' RPE should be considered as an adjunct to a training intensity determined by the percentage of VO_2 peak (peak oxygen consumption; as a measure of exercise capacity), HR, blood pressure, and symptom monitoring because the RPE determined during graded cardiopulmonary exercise testing may not consistently translate to the same intensity as that during exercise training, and a certain percentage of patients are unable to reliably use the RPE scale. Since during exercise, ratings of fatigue and dyspnea are often differently perceived, both symptoms should be monitored separately.^{10,12}

Although there is no consensus as to which methods and exercise intensities are better for the treatment of HF patients, the sub-maximum seems to offer a better safety/efficiency balance.¹³ The most recent Australian guidelines recommend moderate-intensity training at 40–70% VO_2 peak

with a graded increment in duration of exercise, initially from 10 to 15 minutes and increasing to 45–60 minutes per session.¹⁴

Studies have also looked into added utility of higher intensity exercise when compared to low–moderate-intensity levels, and have been postulated to have further beneficial effects on VO_2 peak, left ventricular (LV) remodeling, endothelial function, as well as mitochondrial function. Patwala et al.¹⁵ have shown significant added improvement in VO_2 peak after a high-intensity training program that comprised 80–90% of peak HR. This additional benefit was more than that obtained after cardiac resynchronization therapy (CRT).

Although aerobic training (AT) remains the frontline of recommendations, resistance training has been associated with increased muscle power, endurance, and peripheral blood flow.^{16,17} Levinger et al.¹⁸ examined the effects of resistance training vs. usual activity in patients with HF and found modest improvements in resting EF despite unchanged LV volumes. A similar study examined the effect of resistance training on the capacity to perform activities of daily living (ADLs) and quality of life (QoL) in individuals with high number of metabolic risk factors (HiMF) compared with individuals with a low number of metabolic risk factors (LoMF).¹⁹ Resistance training improved muscle strength and the capacity to perform ADLs in individuals with HiMF and LoMF. Resistance training improved QoL for the HiMF group, and this result was independent of changes in body fat content or aerobic power. A recent systemic review to evaluate resistance training, either alone or as an adjunct to AT, for improving cardiac function, exercise capacity, and QoL in people with HF²⁰ concluded that resistance training increased six-minute walk distance compared to no training, but had no other benefits on cardiac function, exercise capacity, or QoL if used alone or as an adjunct to AT in people with chronic HF.

Similarly, another recent study compared the combined aerobic and resistance training (ART) with an AT in a population of obese type 2 diabetic patients and metabolic syndrome. A total of 47 patients were randomly assigned to aerobic (27 patients) or aerobic plus resistance (20 patients) exercise trainings. Although this study did not particularly focus HF patients, it did show the difference in effects on the related outcomes. Both exercise programs equally improved body weight. Mean blood pressure (AT: –3.6 mmHg vs. ART: +0.6 mmHg, $P < 0.05$) and endothelin-1 (ET-1) incremental areas during walking test (AT: –11% vs. ART: +30%, $P < 0.0001$) decreased after AT and increased after ART. Adiponectin levels increased by 54% after AT, while decreased by 13% after ART ($P < 0.0001$) and matrix metalloproteinase-2 (MMP-2), tumor necrosis factor- α (TNF- α), and monocyte chemoattractant protein-1 (MCP-1) levels significantly decreased in AT, while increased in the ART group. This study suggested that ART, as compared with AT, similarly enhanced body weight loss but exerted less positive effects on insulin sensitivity and endothelial factors, adipokines, and proinflammatory marker release.²¹ Beckers et al also reported



that when comparing with RT alone, six months of ART resulted in a greater improvement of submaximal exercise capacity, upper extremity muscle strength, and cardiac symptoms.¹⁶

Despite the HF being a condition affecting primarily the elderly population, most of the studies have excluded patients with an age >70 years. Wisloff et al.²² studied 27 patients with stable post-infarction HF with a mean age of 75.5 ± 11.1 years who were randomized to either moderate continuous training (MCT) (70% of peak HR) or aerobic interval training (AIT) (95% of peak HR) three times per week for 12 weeks or to a control group. The major finding of this study was that AIT was superior to MCT in patients with post-infarction HF with regard to LV remodeling reversal, aerobic capacity, endothelial function, and QoL. It demonstrated that high-intensity training relative to the individual's maximal oxygen uptake is feasible even in elderly patients.

In summary, although there is no expert consensus on the mode of exercise, combined resistance and AT is likely to optimize the benefits by acting on both the central and peripheral pathways. It is superior to aerobic exercise alone for improving QoL, endurance, and muscle strength.¹⁶ A training approach to combined ART can minimize hemodynamic burden by focusing on small muscle groups and maximizing peripheral adaptations.¹⁴ The benefits of resistance training in isolation are not clear. Any recommendation for exercise training in HF should be based on the particular pathology of the patient, the individual's response to exercise (including HR, blood pressure, symptoms, and perceived exertion), and measurements obtained during cardiopulmonary exercise testing. Additionally, patient's individual status, including current medication, risk factor profile, behavioral characteristics, personal goals, and exercise preferences, should be taken into consideration.¹⁰ Absolute and relative contraindications for exercise training in HF patients are outlined in Table 1.

Pathophysiology of Exercise Intolerance in HF

Mechanisms involving the cellular metabolism and intracellular energy transfer in cardiac as well as skeletal muscle, sympathetic neural activation, and inflammatory cytokines, all possibly contribute to the development of exercise intolerance in HF (Table 2). Although central factors, such as EF or cardiac output, do play a role, it is mostly peripheral factors that are responsible for the reduction in exercise capacity.²³

Central pathophysiology and exercise intolerance.

Cardiac causes.

1. LV dysfunction is characterized by a decrease in EF from the normal range of 60–70% to less than 45%.⁸ This is followed by a reduction in stroke volume (SV)²⁴ and cardiac output, first during exercise and then subsequently at rest.^{25,26} Although abnormalities in the central hemodynamic response have been described in patients with HF, there remains the paradox that measures of resting ventricular function, such as EF, demonstrate a poor correlation with exercise capacity.^{27–29} However, an improvement in exercise capacity after CRT may be in part because of the improvement in systolic function.¹⁵ The response to exercise in the patient with systolic HF is characterized by inadequate LV shortening with increases in end-systolic and end-diastolic volumes. Diastolic dysfunction, on the other hand, is characterized by impaired LV distensibility during exercise, resulting in a rapid rise in LV diastolic pressure and pulmonary capillary wedge pressure that result in symptoms of dyspnea.²⁹
2. Reduced cardiac output because of a low SV as well as a lower HR reserve.³⁰
3. Elevated LV pressure can lead to pulmonary congestion, particularly on exercise, which may result in secondary pulmonary hypertension with time. This in turn may affect the right ventricular function.⁴

Table 1. Contraindications for exercise training in HF¹⁴.

ABSOLUTE CONTRAINDICATIONS	RELATIVE CONTRAINDICATIONS
Progressive worsening of exercise tolerance or dyspnea at rest or on exertion over previous 3–5 days	≥2 kg increase in body mass over previous 1–3 days
Significant ischemia at low exercise intensities (<2 METS, or <50 W)	Concurrent continuous or intermittent dobutamine therapy
Uncontrolled diabetes	Decrease in systolic blood pressure with exercise
Acute systemic illness or fever	New York Heart Association Functional Class IV
Recent embolism	Complex ventricular arrhythmia at rest or appearing with exertion
Thrombophlebitis	Supine resting heart rate ≥100 bpm
Active pericarditis or myocarditis	Pre-existing comorbidities
Severe aortic stenosis	Moderate aortic stenosis
Regurgitant valvular heart disease requiring surgery	BP >180/110 mmHg (evaluated on a case by case basis)
Myocardial infarction within previous 3 weeks	
New onset atrial fibrillation	
Resting heart rate >120 bpm	

**Table 2.** Pathophysiological causes of exercise intolerance in HF and improvement in these pathologies that is associated with exercise.

PATHOPHYSIOLOGY	IMPROVEMENT ASSOCIATED WITH EXERCISE
Central causes <ul style="list-style-type: none"> • Left ventricular dysfunction leading to reduced stroke volume and cardiac output • Reduce chronotropic reserve • Pulmonary congestion secondary to LV dysfunction • Functional mitral regurgitation • Exaggerated minute ventilation relative to carbon dioxide production • Pulmonary structural abnormalities • Poor inspiratory muscle performance 	<ul style="list-style-type: none"> • Improvement of cardiac output at peak exercise level • Reduction of resting left ventricular end-diastolic diameter • Reduced left ventricular diastolic wall stress • 30% increase in VO₂peak • Improved functional capacity in people with dilated cardiomyopathy and diastolic dysfunction • Inspiratory muscle training improves symptoms, VO₂peak and cardiac performance
Peripheral causes <ul style="list-style-type: none"> • Reduced skeletal mass • Alteration in skeletal fiber from type 1 to type IIb • Decrease skeletal oxidative metabolism and ATP production • Endothelial dysfunction • Dysregulated neurohumoral system • Production of inflammatory cytokines 	<ul style="list-style-type: none"> • Improved skeletal mitochondrial load and oxidative metabolism • Reverse-shift from type IIb skeletal muscle fibers to type I • Improved peripheral blood flow with more efficient energy delivery • Improvement of endothelial dysfunction • Reduced NADPH and ROS generation • Reduced sympathetic activity • Reduced production of TNF-α and IL-6

4. Functional mitral regurgitation (MR) can be a consequence of dilated cardiomyopathy or papillary muscle dysfunction leading to reduced SV.^{31,32}
5. Reduced chronotropic reserve in HF, ie, an inability to increase the HR in response to exercise, will lead to failure to increase cardiac output and result in dyspnea during exercise.³³

Respiratory causes.

1. Exaggerated minute ventilation relative to carbon dioxide (CO₂) production – irrespective of the presence of pulmonary congestion, exercise in HF patients will result in a marked rise in minute ventilation, out of proportion to the respiratory rate-dependent raised CO₂ production, contributing to potential significant pulmonary ventilation/perfusion mismatch.^{34,35}
2. Structural abnormalities such as fibrosis and vascular injury, related to pulmonary hypertension and venous congestion, have been seen in HF.^{35,36}
3. Alveolar edema secondary to pulmonary congestion.^{35,36}
4. Poor inspiratory muscle performance is associated with dyspnea, poor exercise tolerance, and poor functional status in HF. Inspiratory muscle training has been observed to improve dyspnea, QoL, peripheral muscle and peripheral blood flow, HR, respiratory rate, VO₂peak, and several indices of cardiac performance.³⁷

Peripheral pathophysiology and exercise intolerance.

While some studies claimed that poor exercise capacity in patients with HF is caused by a reduction in EF³⁸ and cardiac output,^{39,40} most researchers have suggested that changes in the periphery are the main contributors to poor exercise capacity in these patients. These alterations include an increase in peripheral vascular resistance, changes in skeletal muscle metabolism, and reduction in skeletal muscle blood flow, mass, and strength.^{41–48}

Skeletal muscle causes.

1. A reduced skeletal muscle mass has been seen in HF patients,⁴⁹ which in turn has been associated with reduced exercise capacity.⁴⁶
2. An alteration in fiber type from type I to type IIb has been seen in HF patients. These type IIb fibers have fast vs. slow twitching and glycolytic vs. oxidative properties and affect aerobic exercise capacity adversely.⁵⁰
3. Decreased oxidative metabolism and adenosine triphosphate (ATP) production – With maximal exercise testing, the HF patients typically report leg fatigue. This fatigue is associated with increased lactate release from the legs, evidence supportive of skeletal muscle dysfunction. Lactate levels correlate closely with maximal exercise capacity, suggesting a link between muscle dysfunction and exercise intolerance in HF. One study suggests that neither reduction in muscle oxidative capacity nor reduction in capillary density appears to be the cause of exercise limitation in patients with HF.⁵¹ In this study, VO₂peak was determined in 14 HF patients and 8 healthy sedentary similar-age controls. Muscle samples were analyzed for mitochondrial ATP production rate (MAPR), oxidative and glycolytic enzyme activity, fiber size and type, and capillary density. HF patients demonstrated a lower VO₂peak (15.1 ± 1.1 vs. 28.1 ± 2.3 mL·kg⁻¹·min⁻¹, $P < 0.001$) and capillary to fiber ratio (1.09 ± 0.05 vs. 1.40 ± 0.04, $P < 0.001$) when compared with controls. However, there was no difference in capillary density (capillaries per square millimeter) across any of the fiber types. Measurements of MAPR and oxidative enzyme activity suggested no difference in muscle oxidative capacity between the groups. Based on these findings, the authors hypothesized that the low VO₂peak observed in HF patients may be the result of fiber atrophy and possibly impaired activation of oxidative phosphorylation.



Studies have shown that patients who suffer from moderate–severe LV impairment have a reduced mitochondrial density and oxidative enzyme activity (citrate synthases and β -hydroxyacyl CoA dehydrogenase).^{52–56} Drexler et al.⁵⁷ found a decrease in both surface density and volume density of mitochondrial cristae (20% and 17%, respectively) in patients with severe CHF. These changes were consistent with a reduced oxidative capacity of skeletal muscle, from ~60% of mitochondria in normal subjects to ~17% of mitochondria in HF patients. As a result of reduction in oxidative enzyme activity, carbohydrate would be utilized as a source of energy instead of fat, which may result in early anaerobic metabolism and fatigue.⁵⁶ Kemp et al.⁵⁸ found that the non-oxidative ATP cost of work had increased by 150% during exercise in HF patients and was followed by glycogenolytic production, while there was a reduction in the oxidative cost by 26%. Furthermore, they reported a decrement in cytosolic pH with an increase in glycogenolysis during exercise when compared to the control group.

Both activity of oxidative enzymes and mitochondrial cristae surface density showed significant correlation with ventilator threshold and VO_2peak in patients with HF (r between 0.56 and 0.82).^{57,59–63} These findings suggest that a reduction in mitochondria number and/or its inability to utilize the oxygen delivered (secondary to a decrease in oxidative enzymes) may have contributed to the reduction in oxidative capacity, leading to an early onset of anaerobic metabolism and lactate production.^{55,60,64,65}

Other peripheral causes. Endothelial dysfunction (associated with lower nitric oxide (NO) and impaired vasodilatory response to shear stress) and defects in neurohumoral system affecting sympathetic and parasympathetic activities, and proinflammatory cytokines, all have been associated with reduced exercise capacity in HF patients.^{41–48}

Studies in the past decade have suggested that specific alterations in HFPEF consist of cardiomyocyte hypertrophy and interstitial fibrosis, whereas functional changes include incomplete relaxation of myocardial strips and increased cardiomyocyte stiffness. Furthermore, abnormal intramyocardial signaling evident from endothelial cells expressing adhesion molecules, inflammatory cells secreting profibrotic transforming growth factor β (TGF- β), and oxidative stress increasing nitrotyrosine content are also seen in this population.⁶⁶ In HFPEF, comorbidities contribute to a systemic inflammatory state, which induces oxidative stress in the coronary microvascular endothelium. This reduces myocardial NO bioavailability and leads to reduced protein kinase G activity in cardiomyocytes, which therefore become stiff and hypertrophied. This differs from myocardial remodeling in HFREF, which is driven by cardiomyocyte death because of oxidative stress originating in the cardiomyocytes as a result of ischemia, infection, or toxicity.⁶⁶

HFPEF and exercise intolerance. It has been postulated that patients with HFPEF have concomitant arterial

stiffening, contributing to increased LV afterload and alterations of systolic and diastolic functions, particularly during exercise.^{67,68} The increased afterload consequently affects the diastolic filling, again particularly during exercise when a more efficient diastolic filling pressure is required,²⁹ and atrial function becomes a significant determinant of LV filling, thus leading to increased LV filling pressure.^{69–71} Ultimately, it is the combined relationship between central and peripheral mechanisms, as detailed above, that forms the global ventricular–vascular interaction, and importantly, it is this relationship during exercise that contributes to HF symptoms.⁷² Owing to the known beneficial effects on peripheral vascular resistance, arterial stiffening, and abnormalities of skeletal muscle metabolism in the HFPEF syndrome, exercise training presents a viable management and therapeutic tool.⁷²

Benefits of Exercise in HF

Many exercise benefits for HF patients have been documented, such as improvements in physical capacity (an increase in 10–30% of the maximum physical capacity),^{73,74} QoL,⁷⁵ endothelial dysfunction,⁷⁶ circulating catecholamine levels,⁷⁷ morbidity, and hospital admissions.⁷⁸ These above-mentioned changes lead to increased overall exercise capacity with a lower required HR. Exercise training is now widely used as an adjunct therapy for the stable HF patients⁷⁹ with class 1 recommendation by the American College of Cardiology (ACC) and the AHA.⁸⁰

Most HF trials have used moderate/high-intensity exercises (70–80% of peak HR). A lower intensity program of 40–50% VO_2peak has also been shown to improve the exercise capacity.⁷⁵ The recent “Heart Failure – A Controlled Trial Investigating Outcomes of exercise TraiNing” (HF-ACTION) trial, a multicentre, randomized controlled trial looking at 2,331 HF patients with $\text{EF} \leq 35\%$, and New York Heart Association functional classes II–IV showed a nonsignificant reduction in the primary combined end-point of all-cause mortality or hospital stay (HR: 0.93; $P = 0.13$) after a moderate-intensity training followed by home-based training with a total of 30 months median follow-up. Furthermore, no difference in mortality was observed between the exercise and control arms (16% vs. 17%). Significant improvement in VO_2peak was, however, noted in the exercise group (0.6 vs. 0.2 mL/kg/minute). It was, however, noted that only approximately 40% of the exercise group reported a training reaching the prescribed duration of 1.5 hours/week for the first three months, which would likely account for only modest increase in VO_2peak , impacting on statistical differences in outcomes between the exercise and control arms.⁸¹ As far as the adverse events related to exercise in HF patients are concerned, HF-ACTION showed no difference during the entire study period.⁸¹

Role of exercise in HFPEF. Major trials to assess exercise training in HF have focused on HFREF. Since the patients with HFPEF also experience exercise intolerance, dyspnea, early fatigue, and similar mortality risk and



rehospitalization rates, a case can be made for exercise to be part of the management of people with HFPEF.⁷⁹

Gary et al.⁸² have evaluated effects of exercise training on elderly women with HFPEF. A total of 32 women with New York Heart Association classes II and III HFPEF (LV EF >45% and symptoms of dyspnea or fatigue) were randomized into a 12-week home-based, low-to-moderate-intensity (40% and 60%, respectively) exercise and education program (intervention) or only education program (control). The intervention group improved in the six-minute walk test (+20% vs. -11%). Improved QoL and depression were also reported. Similar findings were demonstrated by Smart et al.⁸³ among 18 patients with HFPEF who improved their QoL and exercise capacity by 30%, although without a change in diastolic dysfunction. Kitzman et al.⁸⁴ randomized 53 patients with HFPEF to either a three days per week exercise program or control group. Increased exercise capacity and physical score (measured on Minnesota Living with Heart Failure Questionnaire) were seen after 16 weeks of training, while no change was observed in neuroendocrine or LV function.

Diabetes is common in HFPEF patients and is associated with increased ventricular stiffness. Subclinical diastolic dysfunction without HFPEF is a common complication of type 2 diabetes mellitus (T2DM) that is independently associated with poor cardiovascular outcomes.⁸⁵ To date, no study has demonstrated the ability to alter the progression of diastolic dysfunction in diabetes. Hare et al have studied the impact of an exercise-lifestyle intervention on diastolic dysfunction in patients with T2DM.⁸⁵ In all, 223 outpatients with T2DM were randomized to supervised exercise-lifestyle intervention or usual care. Patients receiving the intervention were randomized to a two-stage supervised exercise program that comprised an initial four-week gym-based exercise program of two 1-hour exercise sessions per week, supervised by an exercise physiologist, with a further 30 minutes of home-based exercise. Each individualized program sought to provide at least moderate exertion using a combination of both aerobic and resistance exercises. The subsequent home-based program was supported by telephone counseling, with an emphasis on maintenance and improvement. This contact was initially weekly and then once every two weeks for three months, with monthly follow-up thereafter. Patients underwent echocardiographic assessment of diastolic function, metabolic and clinical evaluations at baseline and three years. Diastolic dysfunction was present in 50% of patients at baseline and 54% of patients at three years, with no difference between usual care and intervention groups (60% vs. 48%, $P = 0.10$). Abnormal diastolic function at the final visit was independently associated with older age and a decrease in VO₂peak over time ($P < 0.05$). In a sub-analysis restricted to those who finished the full three-year follow-up, control subjects were independently associated with diastolic dysfunction at three years ($\beta = 0.90$, OR = 2.46, $P = 0.034$), with the only other independent correlate being older age ($\beta = 0.05$, OR = 1.06, $P = 0.019$). In this study, three

years of exercise-based lifestyle intervention was not effective in reducing progression of subclinical diastolic dysfunction in patients with T2DM.

A recent systematic review to assess the effect of exercise training in patients with HFPEF suggested benefit in terms of enhancements in exercise capacity and health-related QoL, and the exercise training appeared to be safe.⁷² The review included studies for a total of 228 individuals, and the combined duration of exercise programs and follow-up ranged from 12 to 24 weeks. No deaths, hospital admissions, or serious adverse events were observed during or immediately following exercise training. Compared to control, the change in exercise capacity at follow-up was higher with exercise training. There was evidence of a larger gain in health-related QoL with exercise training. The largest study included in the review showed some evidence of improvement in the E/e' ratio with exercise training, but this was not confirmed in the other studies; E/A ratios were not changed. Thus, despite the benefit of improved exercise capacity and QoL, the impact on diastolic function remains unclear. Further trials should provide data on long-term effects, prognostic relevance, and cost-effectiveness.⁷²

Cardiac effects. Exercise training at submaximal levels in HF has no effect on cardiac output⁸⁶⁻⁸⁸ and slight improvement at peak exercise levels.^{77,87} Hambrecht et al.⁷⁷, on the other hand, demonstrated reductions in resting left ventricular end-diastolic diameter (LVEDD), suggesting a training-induced reverse remodeling. Furthermore, reduced LV diastolic wall stress even at low-moderate workload (50% VO₂peak) has been seen along with a 30% increase in VO₂peak after two months.⁸⁹ Belardinelli et al.⁹⁰ demonstrated improvement in the functional capacity of people with dilated cardiomyopathy and diastolic dysfunction with training. This improvement was, however, limited to people with delayed relaxation. Restrictive cardiomyopathy in this study was associated with a worse prognosis.

Peripheral effects. Reversible peripheral abnormalities in HF patients include changes in skeletal muscle and vasomotor tone. Exercise training can improve mitochondrial load with improved oxidative metabolism.^{86,91,92} A reverse-shift from type IIb skeletal muscle fibers to type I has also been demonstrated, which is associated with improved exercise capacity.⁶¹ An improved peripheral blood flow and more efficient oxygen delivery have also been seen after exercise training.⁸⁸ A beneficial effect on endothelial dysfunction, likely NO mediated as suggested by Hambrecht et al.⁷⁷, and endothelium-dependent peripheral blood flow has been associated with improved VO₂peak.⁷⁶

Furthermore, messenger ribonucleic acid expression of nicotinamide adenine dinucleotide phosphate (NADPH) oxidase activity and reactive oxygen species (ROS) generation responsible for angiotensin II-mediated vasoconstriction has been seen to reduce with exercise.^{93,94} A decrease in sympathetic activity has also been demonstrated.⁹⁵⁻⁹⁸ Reduced levels of the inflammatory cytokines TNF- α and interleukin-6



(IL-6) after training are again associated with an improved exercise capacity.^{99,100}

Exercise Training in HF Patients with Artificial Devices

Exercise training in patients with implantable cardiac devices (ICDs/CRT) has been reported to improve QoL and exercise capacity and seems to be safe.¹⁰¹ Furthermore, it can also have a positive effect on anxiety in ICD patients and can reduce the fear of exercise.^{102–104} Care should, however, be taken for the maximum training HR not to exceed the ICD-intervention HR to avoid any inappropriate shocks. Avoiding a physical trauma to the device, including activities with pronounced arm/shoulder movements, is also sensible.¹⁰⁵ It is recommended that exercise HR reach no higher than 10–15 beats below the ICD tachycardia threshold. Furthermore, upper body resistance exercise should be restricted until six weeks after implantation to prevent dislodgement of newly implanted device leads and healing of the defibrillator site.¹⁴

Potential Risks Associated with Exercise Therapy in HF

Exercise training in HF patients is considered safe. Sudden cardiac death (SCD) during exercise is rare in apparently healthy individuals. Individuals with cardiac disease seem to be at a higher risk than healthy individuals. The incidence of major cardiovascular complications during outpatient cardiac exercise programs has been estimated to be 1 in 60,000 participant-hours.¹⁰⁶ Myocardial infarction is another risk associated with participation in exercise and is more likely to occur than SCD. It is highly recommended that a patient should undergo a symptom-limited graded exercise test prior to commencement of exercise training. This test, along with the clinical assessment and measurement of LV function, is used to determine the safety to commence an unmonitored exercise program by excluding myocardial ischemia, determining ischemic thresholds for those in whom complete control of ischemia is not possible, excluding exercise-induced ventricular tachycardia, determining ventricular rate control in patients with atrial fibrillation, assessing functional capacity, and measuring both work rates and HRs at submaximal and maximal levels of exercise.¹⁴ The health professional should be capable of monitoring, managing, and reporting signs and symptoms of worsening HF, excessive shortness of breath or fatigue, and vasovagal signs and symptoms, including bradycardia, excessive sweating, dizziness, confusion, and acute hypotension that may lead to syncope. All adverse events related to exercise must be reported promptly to the primary care medical practitioner or emergency medical personnel.¹⁴

Conclusion

Exercise intolerance through various mechanisms is the major incapacitating issue in HF patients, and exercise training programs have shown to improve functional capacity, QoL,

dyspnea, as well as HF-related lassitude. Clinical trials have demonstrated a multitude of benefits affecting exercise capacity, metabolic function, vascular tone, cytokine production, and neural activation. Tailored exercise prescription for the modality and intensity, by assessing and interpreting clinical information and applying the principles of training to develop an appropriate regimen, is important to ensure efficiency and safety of the program. Regular exercise results in a modest reduction in risk for clinical events, with even greater benefits likely in patients who adhere to a higher volume of exercise. The impact of exercise training on diastolic function, however, remains less clear as there is inadequate information of long-term outcomes in HFPEF patients, including mortality, hospitalization, and cost-effectiveness. Nevertheless, it appears safe, and further trials in objectively defined HFPEF populations are required.

Author Contributions

Literature search and review: MAUH, CG. Wrote the first draft of the manuscript: MAUH. Contributed to the writing of the manuscript: CY, IL. Agree with manuscript: IL, CW, DH. Jointly developed the structure and arguments for the paper: MAUH, CY, DH. Made critical revisions and approved final version: CY, DH. All authors reviewed and approved of the final manuscript.

REFERENCES

1. Lloyd-Jones D, Adams RJ, Brown TM, et al. Heart disease and stroke statistics – 2010 update: a report from the American Heart Association. *Circulation*. 2010;121(7):e46–215.
2. Asrar UI Haq M, Wong C, Hare DL. Heart failure with preserved ejection fraction: an insight into its prevalence, predictors and implications of early detection. *Rev Cardiovasc Med*. 2014;15:4.
3. Asrar UI Haq M, Mutha V, Rudd N, Hare DL, Wong C. Heart failure with preserved ejection fraction – unwinding the diagnosis mystique. *Am J Cardiovasc Dis*. 2014;4(3):100–13.
4. Asrar ul Haq M, Wong C. Heart failure with preserved myocardial contractility: understanding the pathophysiology. *Eur J Healthb*. 2013;2013:6.
5. Coats AJ, Adamopoulos S, Meyer TE, Conway J, Sleight P. Effects of physical training in chronic heart failure. *Lancet*. 1990;335(8681):63–6.
6. Francis DP, Shamim W, Davies LC, et al. Cardiopulmonary exercise testing for prognosis in chronic heart failure: continuous and independent prognostic value from VE/VCO(2)slope and peak VO(2). *Eur Heart J*. 2000;21(2):154–61.
7. Mancini DM, Eisen H, Kusumaul W, Mull R, Edmunds LH Jr, Wilson JR. Value of peak exercise oxygen consumption for optimal timing of cardiac transplantation in ambulatory patients with heart failure. *Circulation*. 1991;83(3):778–86.
8. Dickstein K, Cohen-Solal A, Filippatos G, et al; ESC Committee for Practice Guidelines (CPG). ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the diagnosis and treatment of acute and chronic heart failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). *Eur Heart J*. 2008;10(10):933–89.
9. Pina IL, Apstein CS, Balady GJ, et al. Exercise and heart failure: a statement from the American Heart Association Committee on exercise, rehabilitation, and prevention. *Circulation*. 2003;107(8):1210–25.
10. Working Group on Cardiac Rehabilitation and Exercise Physiology, Working Group on Heart Failure of the European Society of Cardiology. Recommendations for exercise training in chronic heart failure patients. *Eur Heart J*. 2001;22(2):125–35.
11. Borg GA. Psychophysical bases of perceived exertion. *Med Sci Sports Exerc*. 1982;14(5):377–81.
12. Levinger I, Bronks R, Cody DV, Linton I, Davie A. Perceived exertion as an exercise intensity indicator in chronic heart failure patients on beta-blockers. *J Sports Sci Med*. 2004;3(YISI 1):23–7.



13. Meyer T, Gorge G, Schwaab B, et al. An alternative approach for exercise prescription and efficacy testing in patients with chronic heart failure: a randomized controlled training study. *Am Heart J*. 2005;149(5):e1-7.
14. Selig SE, Levinger I, Williams AD, et al. Exercise & sports science Australia position statement on exercise training and chronic heart failure. *J Sci Med Sport*. 2010;13(3):288-94.
15. Patwala AY, Woods PR, Sharp L, Goldspink DF, Tan LB, Wright DJ. Maximizing patient benefit from cardiac resynchronization therapy with the addition of structured exercise training: a randomized controlled study. *J Am Coll Cardiol*. 2009;53(25):2332-9.
16. Beckers PJ, Denollet J, Possemiers NM, Wuyts FL, Vrints CJ, Conraads VM. Combined endurance-resistance training vs. endurance training in patients with chronic heart failure: a prospective randomized study. *Eur Heart J*. 2008;29(15):1858-66.
17. Selig SE, Carey MF, Menzies DG, et al. Moderate-intensity resistance exercise training in patients with chronic heart failure improves strength, endurance, heart rate variability, and forearm blood flow. *J Card Fail*. 2004;10(1):21-30.
18. Levinger I, Bronks R, Cody DV, Linton I, Davie A. The effect of resistance training on left ventricular function and structure of patients with chronic heart failure. *Int J Cardiol*. 2005;105(2):159-63.
19. Levinger I, Goodman C, Hare DL, Jerums G, Selig S. The effect of resistance training on functional capacity and quality of life in individuals with high and low numbers of metabolic risk factors. *Diabetes Care*. 2007;30(9):2205-10.
20. Hwang CL, Chien CL, Wu YT. Resistance training increases 6-minute walk distance in people with chronic heart failure: a systematic review. *J Physiother*. 2010;56(2):87-96.
21. Lucotti P, Monti LD, Setola E, et al. Aerobic and resistance training effects compared to aerobic training alone in obese type 2 diabetic patients on diet treatment. *Diabetes Res Clin Pract*. 2011;94(3):395-403.
22. Wisloff U, Stoylen A, Loennechen JP, et al. Superior cardiovascular effect of aerobic interval training versus moderate continuous training in heart failure patients: a randomized study. *Circulation*. 2007;115(24):3086-94.
23. Coats AJ. The "muscle hypothesis" of chronic heart failure. *J Mol Cell Cardiol*. 1996;28(11):2255-62.
24. Little WC. Assessment of normal and abnormal cardiac function. In: Braunwald E, Zipes DP, Libby P, eds. *Heart Disease: A Textbook of Cardiovascular Medicine*. 1. Philadelphia: W.B. Saunders Company; 2001:479-502.
25. Gheorghade M, Cody RJ, Francis GS, McKenna WJ, Young JB, Bonow RO. Current medical therapy for advanced heart failure. *Heart Lung*. 2000;29(1):16-32.
26. Piccirillo G, Raffaele Q, Fimognari F, et al. Influence of L-arginine and vitamin C on the autonomic nervous system in chronic heart failure secondary to ischemic cardiomyopathy. *Am J Cardiol*. 2004;93(5):650-4.
27. Franciosa JA, Park M, Levine TB. Lack of correlation between exercise capacity and indexes of resting left ventricular performance in heart failure. *Am J Cardiol*. 1981;47(1):33-9.
28. Fleg JL, O'Connor F, Gerstenblith G, et al. Impact of age on the cardiovascular response to dynamic upright exercise in healthy men and women. *J Appl Physiol*. 1995;78(3):890-900.
29. Asrar ul Haq M, Mutha V, Lin T, et al. Left ventricular torsional dynamics post exercise for LV diastolic function assessment. *Cardiovasc Ultrasound*. 2014;12(1):8.
30. Sullivan MJ, Knight JD, Higginbotham MB, Cobb FR. Relation between central and peripheral hemodynamics during exercise in patients with chronic heart failure. Muscle blood flow is reduced with maintenance of arterial perfusion pressure. *Circulation*. 1989;80(4):769-81.
31. Yiu SF, Enriquez-Sarano M, Tribouilloy C, Seward JB, Tajik AJ. Determinants of the degree of functional mitral regurgitation in patients with systolic left ventricular dysfunction: a quantitative clinical study. *Circulation*. 2000;102(12):1400-6.
32. Trichon BH, O'Connor CM. Secondary mitral and tricuspid regurgitation accompanying left ventricular systolic dysfunction: is it important, and how is it treated? *Am Heart J*. 2002;144(3):373-6.
33. Robbins M, Francis G, Pashkow FJ, et al. Ventilatory and heart rate responses to exercise: better predictors of heart failure mortality than peak oxygen consumption. *Circulation*. 1999;100(24):2411-7.
34. Sullivan MJ, Higginbotham MB, Cobb FR. Increased exercise ventilation in patients with chronic heart failure: intact ventilatory control despite hemodynamic and pulmonary abnormalities. *Circulation*. 1988;77(3):552-9.
35. Buller NP, Poole-Wilson PA. Mechanism of the increased ventilatory response to exercise in patients with chronic heart failure. *Br Heart J*. 1990;63(5):281-3.
36. Guazzi M, Reina G, Tumminello G, Guazzi MD. Improvement of alveolar-capillary membrane diffusing capacity with exercise training in chronic heart failure. *J Appl Physiol*. 2004;97(5):1866-73.
37. Cahalin LP, Arena R, Guazzi M, et al. Inspiratory muscle training in heart disease and heart failure: a review of the literature with a focus on method of training and outcomes. *Expert Rev Cardiovasc Ther*. 2013;11(2):161-77.
38. Magnusson G, Kaijser L, Rong H, Isberg B, Sylven C, Saltin B. Exercise capacity in heart failure patients: relative importance of heart and skeletal muscle. *Clin Physiol*. 1996;16:183-95.
39. Cowley AJ, Fullwood LJ, Muller AF, Stainer K, Skene AM, Hampton JR. Exercise capability in heart failure: is cardiac output important after all? *Lancet*. 1991;337:771-3.
40. Weber KT, Janicki JS. Cardiopulmonary exercise testing for evaluation of chronic cardiac failure. *Am J Cardiol*. 1985;55:22A-31.
41. Coats AJS. Exercise rehabilitation in chronic heart failure. *J Am Coll Cardiol*. 1993;22(suppl A):172A-7.
42. Conn EH, Williams RS, Wallace AG. Exercise responses before and after physical conditioning in patients with severely depressed left ventricular function. *Am J Cardiol*. 1982;49:296-300.
43. Tavazzi L, Giannuzzi P. Physical training as a therapeutic measure in chronic heart failure: time for recommendations. *Heart*. 2001;86:7-11.
44. Piepoli M, Clark AL, Volterrani M, Adamopoulos S, Sleight P, Coats AJS. Contribution of muscle afferents to the hemodynamic, autonomic, and ventilatory responses to exercise in patients with chronic heart failure. *Circulation*. 1996;93:940-52.
45. Minotti JR, Johnson EC, Hudson TL, et al. Skeletal muscle responses to exercise training in congestive heart failure. *J Clin Invest*. 1990;86:751-8.
46. Harrington D, Anker SD, Chua TP, et al. Skeletal muscle function and its relation to exercise tolerance in chronic heart failure. *J Am Coll Cardiol*. 1997;30(7):1758-64.
47. Kostis JB, Rosen RC, Cosgrove NM, Shindler DM, Wilson AC. Nonpharmacologic therapy improves functional and emotional status in congestive heart failure. *Chest*. 1994;106:996-1001.
48. Fang ZY, Marwick TH. Mechanism of exercise training in patients with heart failure. *Am Heart J*. 2003;145(5):904-11.
49. Fulster S, Tacke M, Sandek A, et al. Muscle wasting in patients with chronic heart failure: results from the studies investigating co-morbidities aggravating heart failure (SICA-HF). *Eur Heart J*. 2013;34(7):512-9.
50. Mancini DM, Coyle E, Coggan A, et al. Contribution of intrinsic skeletal muscle changes to 31P NMR skeletal muscle metabolic abnormalities in patients with chronic heart failure. *Circulation*. 1989;80(5):1338-46.
51. Williams AD, Selig S, Hare DL, et al. Reduced exercise tolerance in CHF may be related to factors other than impaired skeletal muscle oxidative capacity. *J Card Fail*. 2004;10(2):141-8.
52. De Sousa E, Veksler V, Bigard X, Mateo P, Ventura-Clapier R. Heart failure affects mitochondrial but not myofibrillar intrinsic properties of skeletal muscle. *Circulation*. 2000;102:1844-54.
53. Delp MD, Duan C, Mattson JP, Musch TI. Changes in skeletal muscle biochemistry and histology relative to fiber type in rats with heart failure. *J Appl Physiol*. 1997;83(4):1291-9.
54. Simonini A, Long CS, Dudley GA, Yue P, McElhinny J, Massie BM. Heart failure in rats causes changes in skeletal muscle morphology and gene expression that are not explained by reduced activity. *Circ Res*. 1996;79:128-36.
55. Sullivan MJ, Green HJ, Cobb FR. Skeletal muscle biochemistry and histology in ambulatory patients with long-term heart failure. *Circulation*. 1990;81(2):518-27.
56. Mancini DM, Coyle E, Coggan A, et al. Contribution of intrinsic skeletal muscle changes to 31P NMR skeletal muscle metabolic abnormalities in patients with chronic heart failure. *Circulation*. 1989;80:1338-46.
57. Drexler H, Riede U, Munzel T, Konig H, Funke E, Just H. Alteration of skeletal muscle in chronic heart failure. *Circulation*. 1992;85:1751-9.
58. Kemp GJ, Thompson CH, Stratton JR, et al. Abnormalities in exercising skeletal muscle in congestive heart failure can be explained in terms of decreased mitochondrial ATP synthesis, reduced metabolic efficiency, and increased glycogenolysis. *Heart*. 1996;76(1):35-41.
59. Sullivan MJ, Green HJ, Cobb FR. Altered skeletal muscle metabolic response to exercise in chronic heart failure: relation to skeletal muscle aerobic enzyme activity. *Circulation*. 1991;84:1597-607.
60. Ivy JL, Withers RT, Van Handel PJ, Elger DH, Costill DL. Muscle respiratory capacity and fiber type as determination of the lactate threshold. *J Appl Physiol*. 1980;48(3):523-7.
61. Hambrecht R, Fiehn E, Yu J, et al. Effects of endurance training on mitochondrial ultrastructure and fiber type distribution in skeletal muscle of patients with stable chronic heart failure. *J Am Coll Cardiol*. 1997;29(5):1067-73.
62. Hambrecht R, Fiehn E, Niebauer J, et al. Physical training in patients with congestive heart failure: effects on cardiorespiratory fitness and oxidative of skeletal muscle. *Circulation*. 1994;90(4):1-162.
63. Green HJ, Duscha BD, Sullivan MJ, Keteyian SJ, Kraus WE. Normal skeletal muscle Na-K pump concentration in patients with chronic heart failure. *Muscle Nerve*. 2001;24:69-76.
64. Walker PM, Idstrom JP, Schersten T, Bylund-Fellenius AC. Metabolic response in different muscle types to reduced blood flow during exercise in perfused rat hindlimb. *Clin Sci*. 1982;63:293-9.



65. Dudley GA, Tullson PC, Terjung RL. Influence of mitochondrial content on the sensitivity of respiratory control. *J Biol Chem*. 1987;262(19):9109–14.
66. Paulus WJ, Tschope C. A novel paradigm for heart failure with preserved ejection fraction: comorbidities drive myocardial dysfunction and remodeling through coronary microvascular endothelial inflammation. *J Am Coll Cardiol*. 2013;62(4):263–71.
67. Kawaguchi M, Hay I, Fetcs B, Kass DA. Combined ventricular systolic and arterial stiffening in patients with heart failure and preserved ejection fraction: implications for systolic and diastolic reserve limitations. *Circulation*. 2003;107(5):714–20.
68. Kitzman DW, Higginbotham MB, Cobb FR, Sheikh KH, Sullivan MJ. Exercise intolerance in patients with heart failure and preserved left ventricular systolic function: failure of the Frank-Starling mechanism. *J Am Coll Cardiol*. 1991;17(5):1065–72.
69. Hundley WG, Kitzman DW, Morgan TM, et al. Cardiac cycle-dependent changes in aortic area and distensibility are reduced in older patients with isolated diastolic heart failure and correlate with exercise intolerance. *J Am Coll Cardiol*. 2001;38(3):796–802.
70. Holland DJ, Sacre JW, Leano RL, Marwick TH, Sharman JE. Contribution of abnormal central blood pressure to left ventricular filling pressure during exercise in patients with heart failure and preserved ejection fraction. *J Hypertens*. 2011;29(7):1422–30.
71. Tan YT, Wenzelburger F, Lee E, et al. Reduced left atrial function on exercise in patients with heart failure and normal ejection fraction. *Heart*. 2010;96(13):1017–23.
72. Taylor RS, Davies EJ, Dalal HM, et al. Effects of exercise training for heart failure with preserved ejection fraction: a systematic review and meta-analysis of comparative studies. *Int J Cardiol*. 2012;162(1):6–13.
73. Keteyian SJ, Levine AB, Brawner CA, et al. Exercise training in patients with heart failure. A randomized, controlled trial. *Annals Internal Med*. 1996;124(12):1051–7.
74. Papatheanasiou G, Tsamis N, Georgiadou P, Adamopoulos S. Beneficial effects of physical training and methodology of exercise prescription in patients with heart failure. *Hellenic J Cardiol*. 2008;49(4):267–77.
75. Belardinelli R, Georgiou D, Cianci G, Purcaro A. Randomized, controlled trial of long-term moderate exercise training in chronic heart failure: effects on functional capacity, quality of life, and clinical outcome. *Circulation*. 1999;99(9):1173–82.
76. Hornig B, Maier V, Drexler H. Physical training improves endothelial function in patients with chronic heart failure. *Circulation*. 1996;93(2):210–4.
77. Hambrecht R, Gielen S, Linke A, et al. Effects of exercise training on left ventricular function and peripheral resistance in patients with chronic heart failure: a randomized trial. *JAMA*. 2000;283(23):3095–101.
78. Piepoli MF, Davos C, Francis DP, Coats AJ. Exercise training meta-analysis of trials in patients with chronic heart failure (ExTraMATCH). *BMJ*. 2004;328(7433):189.
79. Asrar ul Haq M, Wong C, Mutha V, et al. Therapeutic interventions for heart failure with preserved ejection fraction: a summary of current evidence. *World J Cardiol*. 2014;6(2):67–76.
80. Hunt SA. ACC/AHA 2005 guideline update for the diagnosis and management of chronic heart failure in the adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (writing committee to update the 2001 guidelines for the evaluation and management of heart failure). *J Am Coll Cardiol*. 2005;46(6):e1–82.
81. O'Connor CM, Whellan DJ, Lee KL, et al. Efficacy and safety of exercise training in patients with chronic heart failure: HF-ACTION randomized controlled trial. *JAMA*. 2009;301(14):1439–50.
82. Gary RA, Sueta CA, Dougherty M, et al. Home-based exercise improves functional performance and quality of life in women with diastolic heart failure. *Heart Lung*. 2004;33(4):210–8.
83. Smart N, Haluska B, Jeffriess L, Marwick TH. Exercise training in systolic and diastolic dysfunction: effects on cardiac function, functional capacity, and quality of life. *Am Heart J*. 2007;153(4):530–6.
84. Kitzman DW, Brubaker PH, Morgan TM, Stewart KP, Little WC. Exercise training in older patients with heart failure and preserved ejection fraction: a randomized, controlled, single-blind trial. *Circ Heart Fail*. 2010;3(6):659–67.
85. Hare JL, Hordern MD, Leano R, Stanton T, Prins JB, Marwick TH. Application of an exercise intervention on the evolution of diastolic dysfunction in patients with diabetes mellitus: efficacy and effectiveness. *Circ Heart Fail*. 2011;4(4):441–9.
86. Belardinelli R, Georgiou D, Scocco V, Barstow TJ, Purcaro A. Low intensity exercise training in patients with chronic heart failure. *J Am Coll Cardiol*. 1995;26(4):975–82.
87. Sullivan MJ, Higginbotham MB, Cobb FR. Exercise training in patients with severe left ventricular dysfunction. Hemodynamic and metabolic effects. *Circulation*. 1988;78(3):506–15.
88. Dubach P, Myers J, Dziekan G, et al. Effect of high intensity exercise training on central hemodynamic responses to exercise in men with reduced left ventricular function. *J Am Coll Cardiol*. 1997;29(7):1591–8.
89. Demopoulos L, Bijou R, Fergus I, Jones M, Strom J, LeJemtel TH. Exercise training in patients with severe congestive heart failure: enhancing peak aerobic capacity while minimizing the increase in ventricular wall stress. *J Am Coll Cardiol*. 1997;29(3):597–603.
90. Belardinelli R, Georgiou D, Cianci G, Berman N, Ginzton L, Purcaro A. Exercise training improves left ventricular diastolic filling in patients with dilated cardiomyopathy. Clinical and prognostic implications. *Circulation*. 1995;91(11):2775–84.
91. Adamopoulos S, Coats AJ, Brunotte F, et al. Physical training improves skeletal muscle metabolism in patients with chronic heart failure. *J Am Coll Cardiol*. 1993;21(5):1101–6.
92. Hambrecht R, Niebauer J, Fiehn E, et al. Physical training in patients with stable chronic heart failure: effects on cardiorespiratory fitness and ultrastructural abnormalities of leg muscles. *J Am Coll Cardiol*. 1995;25(6):1239–49.
93. Hambrecht R, Fiehn E, Weigl C, et al. Regular physical exercise corrects endothelial dysfunction and improves exercise capacity in patients with chronic heart failure. *Circulation*. 1998;98(24):2709–15.
94. Octavia Y, Brunner-La Rocca HP, Moens AL. NADPH oxidase-dependent oxidative stress in the failing heart: from pathogenic roles to therapeutic approach. *Free Radic Biol Med*. 2012;52(2):291–7.
95. Flynn KE, Pina IL, Whellan DJ, et al. Effects of exercise training on health status in patients with chronic heart failure: HF-ACTION randomized controlled trial. *JAMA*. 2009;301(14):1451–9.
96. Kiilavuori K, Toivonen L, Naveri H, Leinonen H. Reversal of autonomic derangements by physical training in chronic heart failure assessed by heart rate variability. *Eur Heart J*. 1995;16(4):490–5.
97. Adamopoulos S, Ponikowski P, Cerquetani E, et al. Circadian pattern of heart rate variability in chronic heart failure patients. Effects of physical training. *Eur Heart J*. 1995;16(10):1380–6.
98. Roveda F, Middlekauff HR, Rondon MU, et al. The effects of exercise training on sympathetic neural activation in advanced heart failure: a randomized controlled trial. *J Am Coll Cardiol*. 2003;42(5):854–60.
99. Adamopoulos S, Parissis J, Karatzas D, et al. Physical training modulates proinflammatory cytokines and the soluble Fas/soluble Fas ligand system in patients with chronic heart failure. *J Am Coll Cardiol*. 2002;39(4):653–63.
100. Gielen S, Adams V, Mobius-Winkler S, et al. Anti-inflammatory effects of exercise training in the skeletal muscle of patients with chronic heart failure. *J Am Coll Cardiol*. 2003;42(5):861–8.
101. Vanhees L, Kornaat M, Defoor J, et al. Effect of exercise training in patients with an implantable cardioverter defibrillator. *Eur Heart J*. 2004;25(13):1120–6.
102. Belardinelli R, Capestro F, Misiani A, Scipione P, Georgiou D. Moderate exercise training improves functional capacity, quality of life, and endothelium-dependent vasodilation in chronic heart failure patients with implantable cardioverter defibrillators and cardiac resynchronization therapy. *Eur J Cardiovasc Prev Rehabil*. 2006;13(5):818–25.
103. Fitchet A, Doherty PJ, Bundy C, Bell W, Fitzpatrick AP, Garratt CJ. Comprehensive cardiac rehabilitation programme for implantable cardioverter-defibrillator patients: a randomised controlled trial. *Heart*. 2003;89(2):155–60.
104. van den Broek KC, Nyklicek I, van der Voort PH, Alings M, Meijer A, Denollet J. Risk of ventricular arrhythmia after implantable defibrillator treatment in anxious type D patients. *J Am Coll Cardiol*. 2009;54(6):531–7.
105. De Maeyer C, Beckers P, Vrints CJ, Conraads VM. Exercise training in chronic heart failure. *Ther Adv Chronic Dis*. 2013;4(3):105–17.
106. Franklin BA, Bonzheim K, Gordon S, Timmis GC. Safety of medically supervised outpatient cardiac rehabilitation exercise therapy: a 16-year follow-up. *Chest*. 1998;114(3):902–6.